Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Navigating 11 Analyst Ratings For 10x Genomics
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
10x Genomics Analyst Ratings
Morgan Stanley Maintains 10x Genomics(TXG.US) With Buy Rating, Cuts Target Price to $46
Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Maintains Target Price $26
Intellia Therapeutics (NTLA) Receives a Buy From J.P. Morgan
Veracyte Analyst Ratings
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $26
JP Morgan Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $55
Analyst Issues Sell Rating for Veracyte Amidst Strong Q2 Growth but Limited Near-Term Upside
CRISPR Therapeutics Analyst Ratings
Buy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash Reserves
Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating
Intellia Therapeutics Analyst Ratings
RBC Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $54
Evercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
Buy Rating Affirmed for 10x Genomics Amidst Strategic Realignment and Promising Growth Prospects
Stifel Nicolaus Reaffirms Their Buy Rating on 10x Genomics (TXG)